Everyone’s Buying AI Chips. Almost Nobody Owns the Outlet.

Analyst Targets

• Citi (Joanne Wuensch): Buy | Target cut to $57 from $61
• BTIG: Buy | Target cut to $56 from $60 — September 9, 2026
• TD Cowen: Buy | Target $56 — reiterated post-cyberattack
• Stifel (Rick Wise): Buy | Target $60 — maintained
• Argus: Downgraded to Hold from Buy

What Changed This Week

Citi’s cut to $57 is the headline, but the number that matters more is $44.98, where BSX closed on Tuesday, September 8, 2026 after the company told investors in an SEC filing that it is likely to have a material impact on Q3 and full-year 2026 results and that it does not expect to meet the net sales growth and adjusted EPS guidance ranges issued in late July. The stock is now down roughly 50% year-to-date, trading near its 52-week floor, and carrying no valid financial forecast until October 28.

This is not a guidance trim. Boston Scientific pulled its numbers entirely.

Company Profile

Boston Scientific (NYSE: BSX) is a Marlborough, Massachusetts-based medical device maker operating across two segments: MedSurg and Cardiovascular. Its portfolio spans electrophysiology, structural heart, endoscopy, urology, and neuromodulation. The Cardiovascular segment, anchored by franchises including WATCHMAN and Farapulse, drives the bulk of revenue. Products are predominantly single-use consumables, a distinction that becomes structurally important when manufacturing halts.

The Cyberattack Sequence

August 25: A cybersecurity incident is identified, triggering a network outage that left the company with limited access to certain IT systems and business applications and caused a global disruption to operations, including order processing and shipping.

August 26: First Form 8-K filed with the SEC. Material impact undetermined at that stage.

September 8: Second 8-K filed. Boston Scientific said the incident is likely to have a material impact on Q3 and full-year 2026 results, and said it does not expect to meet the net sales growth and adjusted EPS guidance ranges issued in late July. No timeline given for full operational recovery.

The Numbers That Are Now Gone

As of late July, Boston Scientific had guided for:

• Full-year adjusted EPS: $3.28 to $3.32
• Full-year net sales growth: 5.5% to 6.5%
• Q3 adjusted EPS: $0.80 to $0.82
• Q3 net sales growth: 3% to 5%

All of it is now suspended. The company will provide its next update alongside Q3 results on October 28.

Why the Recovery Math Is Hard

Some investors are using Stryker as a shorthand comparison, but the recovery shapes do not have to match. Boston Scientific’s portfolio skews toward single-use consumables: if a procedure doesn’t happen, that revenue does not come back. The calendar also matters. With the year already advanced, the window to recover delayed procedures and shipments is compressed.

Distribution is largely restored. Major hubs are processing orders at or above normal throughput, sterilization facilities are back online, and manufacturing has resumed at most facilities globally. But the company has been explicit that the full financial toll is not yet determined.

Forward Scenarios

Bull

October 28 guidance reset lands above the low end of investor expectations. Electrophysiology and Watchman trends prove intact once the operational noise clears. Analysts shift focus to 2027, and the stock begins recovering from a deeply oversold base. Citi’s $57 target represents roughly 25% upside from current levels.

Base

BSX reports a Q3 miss of meaningful size, resets full-year guidance significantly below July levels, and trades sideways into year-end. Stifel’s framing holds: 2026 is written off and the market waits for 2027 visibility.

Bear

The October update reveals larger-than-expected backorder losses in high-margin cardiovascular consumables, and structural weakness in WATCHMAN and EP compounds the damage. The stock tests its 52-week low near $42.

Technical Overlay

BSX has shed more than 50% from its September 2025 all-time closing high of $108.14. The 52-week low sits at $42.20. With no earnings guidance anchoring the stock, price action is likely to remain range-bound between that floor and the $50 area until October 28 provides a hard reset. Activity in options markets also turned more defensive around the September 8 filing.

Bottom Line

The cyberattack did not create Boston Scientific’s 2026 problems. It exposed and accelerated them. The company had already reset guidance in late July, with WATCHMAN slowing and electrophysiology under competitive pressure. What the attack added was a hard stop on every number the company had given investors, plus a six-week blackout before any new ones arrive.

Citi’s cut to $57 and BTIG’s to $56 reflect informed Buy-rated analysts lowering conviction, not abandoning the long-term thesis. The critical question before October 28 is not whether BSX missed Q3, but how much of the missed revenue is recoverable and whether franchise-level trends in cardiovascular are being obscured by operational disruption or genuinely deteriorating. That answer determines whether $45 is a floor or a ceiling.